<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137903</url>
  </required_header>
  <id_info>
    <org_study_id>OM-2010</org_study_id>
    <nct_id>NCT01137903</nct_id>
  </id_info>
  <brief_title>Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers</brief_title>
  <official_title>Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:Surgical treatment of osteomyelitis in diabetic foot is more effective that
      medical treatment through antibiotherapy and leads wound healing in ulcers complicated with
      bone infection.Material and Methods: Randomized clinical trials which include two groups of
      patients (n=88), one receives medical treatment through antibiotherapy during 90 days and the
      other group receive conservative surgical treatment and antibiotics during 7 days after
      surgery. It will be studied differences between both groups in healing time, recidives,
      present and relationship of adverse events and outflow of quality of life related health .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healing patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of diabetic foot ulcers healing in both arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reulceration</measure>
    <time_frame>1 year after healing</time_frame>
    <description>Analysis of re-ulceration events in both arms after healing in a 1 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time</measure>
    <time_frame>12 weeks</time_frame>
    <description>Healing time in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of complications in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life related to health in both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Osteomyelitis</condition>
  <condition>Diabetic Foot</condition>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Patients undergoing medical treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Antibiotic treatment within 90 days with:
Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing surgical treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conservative surgical Minor amputation 7 days antibiotic after surgical</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conservative surgery</intervention_name>
    <description>Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy</description>
    <arm_group_label>Patients undergoing surgical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>500 mg/ 12 hours during 90 days</description>
    <arm_group_label>Patients undergoing medical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Potassium Clavulanate Combination</intervention_name>
    <description>875/125 mg/12 hours during 90 days</description>
    <arm_group_label>Patients undergoing medical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole trimethoprim</intervention_name>
    <description>Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.</description>
    <arm_group_label>Patients undergoing medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Diabetes Mellitus Type 1 or 2.

          -  Patients with diabetic foot ulcers.

          -  Patients with clinical suspects of osteomyelitis.

          -  Patients with positive probe to bone test.

          -  Patients with signs of osteolysis in the bone located adjacent to the ulcer in X-Ray

          -  Patients with transcutaneous oxygen oxygenation above 30 mmHg.

          -  Acceptance to participate in the study through prior informed consent.

        Exclusion Criteria:

          -  Patients with osteomyelitis associated with necrotizing soft tissue infections.

          -  Presence of necrotic tissue in the wound bed, edges or margins of the lesion.

          -  HbAc1 &gt; 10.

          -  Presence of systemic toxicity such as fever, tachycardia, confusion, disorientation,
             vomiting or other signs usually related to systemic infection.

          -  Patients with bone exposure through the ulcer.

          -  Patients with absent pulses, ankle/brachial index (ABI) &lt;0.8 and TcPO2 &lt;30 mmHg.

          -  Pregnancy.

          -  Allergies to antibiotics.

          -  Any degree of renal impairment that contraindicated the administration of antibiotics
             proposed.

          -  Hepatic insufficiency.

          -  Mental Illnesses that prevent the understanding by the patient's proposed treatment,
             or for any other reason associated with your mental health, to recommend their
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Luis Lázaro Martínez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Complutense de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Javier Aragón Sánchez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Paloma Las Palmas de Gran Canaria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Luis Lázaro Martínez, PhD</last_name>
    <phone>+34913942203</phone>
    <email>diabetes@enf.ucm.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>José Luis Lázaro Martínez</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Lázaro Martínez, PhD</last_name>
      <phone>+34913942203</phone>
      <email>diabetes@enf.ucm.es</email>
    </contact>
    <investigator>
      <last_name>Esther Alicia García Morales, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Allas Aguado, DP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Máximo Antonio González Jurado, RN, DP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Rivera San Martín, DP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María del Carmen García Carrión, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Vicente Beneit Montesinos, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Luis Lázaro Martínez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franciso Javier Aragón Sánchez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Almudena Cecilia Matilla, DP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda García Álvarez, RN, DP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>José Luis Lázaro Martínez/Professor</name_title>
    <organization>Universidad Complutense de Madrid</organization>
  </responsible_party>
  <keyword>Diabetic foot</keyword>
  <keyword>Osteomyelitis</keyword>
  <keyword>Diabetic foot ulcers</keyword>
  <keyword>Foot infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

